NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET FORECAST 2019-2028

NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET FORECAST 2019-2028

  • June 2020 •
  • Report ID: 5903633 •
  • Format: PDF
KEY FINDINGS
The North America immunosuppressant drugs market is projected to record growth at a CAGR of 3.19% during the forecast period, 2019-2028. The surge in demand for organ transplantation, as a result of increasing organ failure incidences, is the influential factor in stimulating market growth.

MARKET INSIGHTS
The North America immunosuppressant drugs market growth analysis involves market evaluation of Canada and the United States.Canada has the presence of major pharmaceutical companies.

The pharmaceutical industry of the country comprises of an ecosystem of local and multinational companies.A large part of the Canadian population is affected by autoimmune diseases.

Sjögren’s syndrome is one such autoimmune disorder that is prevalent in Canada.Immunosuppressant drugs are an instrumental part of treatment for such autoimmune disorders.

Over the years, there has been an increase in the NDD (NDD, or neurological determination of death) donors and a decrease in the DCD (donation after cardio-circulatory death) donors. DCD was practiced in the country since 2006. There have also been significant variations in the type of organs being transplanted. Such factors are attributed to the growth of the market under study.

COMPETITIVE INSIGHTS
Some of the eminent companies progressing in the market are Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Astellas Pharma Inc, AbbVie Inc, Cipla Ltd, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned
1. ABBVIE INC
2. ALLERGAN PLC (ACQUIRED BY ABVIE INC)
3. ASTELLAS PHARMA INC
4. BRISTOL-MYERS SQUIBB COMPANY
5. CIPLA LTD
6. DR. REDDY’S LABORATORIES LTD
7. F HOFFMANN-LA ROCHE AG
8. GLAXOSMITHKLINE PLC
9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
10. JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
11. MYLAN NV
12. NOVARTIS INTERNATIONAL AG (SANDOZ)
13. PFIZER INC
14. SANOFI SA
15. VELOXIS PHARMACEUTICALS